new-compound-targets-circadian-clock-machinery-in-cells-to-fight-glioblastoma

In USC-directed investigations, the novel drug candidate specifically targeted glioblastoma stem cells and successfully completed initial safety evaluations in a Phase 1 clinical trial.


Leave a Reply

Your email address will not be published. Required fields are marked *

Share This